MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MBX - CA59501P1045 - Common Stock
0.23 CAD
0 (-2.13%)
We assign a fundamental rating of 6 out of 10 to MBX. MBX was compared to 23 industry peers in the Biotechnology industry. MBX scores excellent on profitability, but there are some minor concerns on its financial health. MBX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make MBX a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year MBX has reported negative net income.
In the past year MBX had a positive cash flow from operations.
In multiple years MBX reported negative net income over the last 5 years.
MBX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -0.85%, MBX belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1.11%, MBX belongs to the top of the industry, outperforming 95.65% of the companies in the same industry.
With an excellent Return On Invested Capital value of 1.38%, MBX belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROIC | 1.38% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of MBX has grown nicely.
MBX's Operating Margin of 3.26% is amongst the best of the industry. MBX outperforms 95.65% of its industry peers.
MBX's Operating Margin has improved in the last couple of years.
The Gross Margin of MBX (55.77%) is better than 91.30% of its industry peers.
MBX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MBX is destroying value.
Compared to 1 year ago, MBX has less shares outstanding
MBX has more shares outstanding than it did 5 years ago.
MBX has a better debt/assets ratio than last year.
2.2 Solvency
MBX has an Altman-Z score of 2.23. This is not the best score and indicates that MBX is in the grey zone with still only limited risk for bankruptcy at the moment.
MBX has a Altman-Z score of 2.23. This is amongst the best in the industry. MBX outperforms 86.96% of its industry peers.
MBX has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.21, MBX is in the better half of the industry, outperforming 60.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.23 |
ROIC/WACC0.19
WACC7.47%
2.3 Liquidity
A Current Ratio of 9.73 indicates that MBX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.73, MBX belongs to the best of the industry, outperforming 91.30% of the companies in the same industry.
A Quick Ratio of 6.15 indicates that MBX has no problem at all paying its short term obligations.
MBX has a better Quick ratio (6.15) than 86.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 |
3. Growth
3.1 Past
MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -106.48%.
MBX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.58% yearly.
Looking at the last year, MBX shows a decrease in Revenue. The Revenue has decreased by -9.53% in the last year.
Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 13.62% on average per year.
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
3.2 Future
Based on estimates for the next years, MBX will show a very strong growth in Earnings Per Share. The EPS will grow by 51.83% on average per year.
MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.86% yearly.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Forward Earnings ratio is 5.69, which indicates a rather cheap valuation of MBX.
100.00% of the companies in the same industry are more expensive than MBX, based on the Price/Forward Earnings ratio.
MBX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.69 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaply inside the industry as 95.65% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.26 |
4.3 Compensation for Growth
MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 51.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
No dividends for MBX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MBX (12/31/2025, 7:00:00 PM)
0.23
0 (-2.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.65%
Ins Owner ChangeN/A
Market Cap31.97M
Revenue(TTM)21.14M
Net Income(TTM)-324.80K
Analysts80
Price Target0.51 (121.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.44%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.69 | ||
| P/S | 1.51 | ||
| P/FCF | N/A | ||
| P/OCF | 53.13 | ||
| P/B | 1.09 | ||
| P/tB | 1.26 | ||
| EV/EBITDA | 11.26 |
EPS(TTM)0
EYN/A
EPS(NY)0.04
Fwd EY17.57%
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFY1.88%
SpS0.15
BVpS0.21
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.85% | ||
| ROE | -1.11% | ||
| ROCE | 1.92% | ||
| ROIC | 1.38% | ||
| ROICexc | 2.09% | ||
| ROICexgc | 2.5% | ||
| OM | 3.26% | ||
| PM (TTM) | N/A | ||
| GM | 55.77% | ||
| FCFM | N/A |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-16.73%
ROICexgc growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score3
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 51.1% | ||
| Cap/Sales | 4.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 25.12% | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.73 | ||
| Quick Ratio | 6.15 | ||
| Altman-Z | 2.23 |
F-Score3
WACC7.47%
ROIC/WACC0.19
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-106.48%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-750%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-31.37%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y-68.79%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y83.08%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y17.98%
OCF growth 3Y27.25%
OCF growth 5Y155.41%
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MBX.CA.
What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.
What is the profitability of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 7 / 10.